214 related articles for article (PubMed ID: 27374176)
21. Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells.
Dan J; Nie L; Jia X; Xu C; Cai J; Lin Y; Hu J; Zhu W; Li Y; Chen D; Liu Y; Hu C; Yan G; Liang J; Zhang Q
Virol Sin; 2021 Aug; 36(4):655-666. PubMed ID: 33481190
[TBL] [Abstract][Full Text] [Related]
22. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
[TBL] [Abstract][Full Text] [Related]
23. Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation.
Chin EC; Abayasekara DR
J Endocrinol; 2004 Oct; 183(1):51-60. PubMed ID: 15525573
[TBL] [Abstract][Full Text] [Related]
24. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer.
Sun S; Liu Y; He C; Hu W; Liu W; Huang X; Wu J; Xie F; Chen C; Wang J; Lin Y; Zhu W; Yan G; Cai J; Li S
Cancer Lett; 2021 Apr; 502():9-24. PubMed ID: 33444691
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
26. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
27. Liposome Encapsulation of Oncolytic Virus M1 To Reduce Immunogenicity and Immune Clearance in Vivo.
Wang Y; Huang H; Zou H; Tian X; Hu J; Qiu P; Hu H; Yan G
Mol Pharm; 2019 Feb; 16(2):779-785. PubMed ID: 30604617
[TBL] [Abstract][Full Text] [Related]
28. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
29. ROS/Epac1-mediated Rap1/NF-kappaB activation is required for the expression of BAFF in Raw264.7 murine macrophages.
Moon EY; Lee JH; Lee JW; Song JH; Pyo S
Cell Signal; 2011 Sep; 23(9):1479-88. PubMed ID: 21596132
[TBL] [Abstract][Full Text] [Related]
30. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
32. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
33. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
35. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
[TBL] [Abstract][Full Text] [Related]
36. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.
Zhao Y; Li H; Wu R; Li S; Wang P; Wang H; Wang J; Zhou J
PLoS One; 2015; 10(5):e0126726. PubMed ID: 25978371
[TBL] [Abstract][Full Text] [Related]
37. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
38. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
39. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.
Holl EK; Brown MC; Boczkowski D; McNamara MA; George DJ; Bigner DD; Gromeier M; Nair SK
Oncotarget; 2016 Nov; 7(48):79828-79841. PubMed ID: 27806313
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.
Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X
Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
